Clinical Trial

PK/PD Analysis of Ceftazidime/Avibactam or Cefiderocol With or Without Fosfomycin for the Treatment of Difficult To-treat Gram-negative Infections

Study acronym: PACCOF
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 21, 2024 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
A multicenter, national, prospective, observational pharmacological study of patients with difficult-to-treat Gram-negative infections treated with ceftazidime/avibactam (CAZ/AVI) or cefiderocol (CEF) monotherapy or combination therapy with ceftazidime/avibactam associated with fosfomycin (FOS) or cefiderocol associated with fosfomycin.
Trial Details
NCT Number NCT06651047
Lead Sponsor University of Bologna
Conditions Gram Negative Infection, Antimicrobial Resistance (AMR)
Enrollment 120 participants
Start Date 2024-07-09
Primary Completion 2025-09-30 (estimated)
Study Completion 2025-09-30 (estimated)
Updated on ClinicalTrials.gov 2024-10-21